603139 Shaanxi Kanghui Pharmaceutical
- 13.91
- -0.05-0.36%
Shaanxi Kanghui Pharmaceutical News
Kanghui Pharmaceutical (603139.SH): Net profit of 1.086 million yuan in the first quarter decreased by 86.76% year on year
On April 26, Ge Longhui Pharmaceutical (603139.SH) released its first quarter report. Operating revenue was 127 million yuan, up 2.89% year on year, and net profit was 1.086 million yuan, down 86.76% year on year. After deducting non-net loss of 119 million yuan, basic earnings per share were 0.01 yuan.
A-share afternoon review: Shanghai index fell 0.52%, AI concept sector led the decline
The main A-share index opened low. As of the midday close, the Shanghai Index fell 0.52% to 3015.74 points, the Shenzhen Stock Exchange Index fell 1.25%, and the GEM index fell 1.46%.
Improved Revenues Required Before Shaanxi Kanghui Pharmaceutical Co., Ltd. (SHSE:603139) Stock's 33% Jump Looks Justified
Shaanxi Kanghui Pharmaceutical Co., Ltd. (SHSE:603139) shareholders are no doubt pleased to see that the share price has bounced 33% in the last month, although it is still struggling to make up recen
Kanghui Pharmaceutical to Earn 151 Million Yuan From Kelavi Buyback
Shaanxi Kanghui Pharmaceutical (SHA:603139) will earn 151.2 million yuan after Hubei Kelavi Biopharmaceutical repurchases its shares from the Chinese drugmaker, according to a disclosure on the Shangh
Kanghui Pharmaceutical (603139.SH): Performance pledger plans to buy back 42.8725% of the company's shares in Clavey
On March 14, Ge Longhui Pharmaceuticals (603139.SH) announced that Hubei Clavey Biopharmaceutical Co., Ltd. (“Clavey”) plans to buy back 42.8725% of the company's shares in cash. The total transaction price for the company's investment in Clavey was RMB 119.98 million. After negotiations between the two parties, the repurchase pricing principle was “original investment amount+capital cost compensation for the period”. The total repurchase price was RMB 151.2069 million, of which the principal amount was RMB 119.98 million and interest was RMB 31.22,900 (interest rate was 10% annualized, and the interest period ended December 3, 2023
Shaanxi Kanghui Pharmaceutical Co., Ltd. (SHSE:603139) Not Doing Enough For Some Investors As Its Shares Slump 26%
Shaanxi Kanghui Pharmaceutical Co., Ltd. (SHSE:603139) shareholders that were waiting for something to happen have been dealt a blow with a 26% share price drop in the last month. Instead of being
Kanghui Pharmaceutical (603139.SH): Pre-loss of 19 million yuan to 28.5 million yuan in 2023
Gelonghui, January 30丨Kanghui Pharmaceutical (603139.SH) announced its 2023 annual results forecast. According to preliminary estimates by the financial department, it is expected that net profit attributable to the owners of the parent company will lose in 2023, achieving net profit attributable to the owners of the parent company - 28.5 million yuan to -19 million yuan. It is expected to achieve net profit of 36 million yuan to -26.5 million yuan after deducting non-recurring profit and loss attributable to the owners of the parent company in 2023.
Kanghui Pharmaceutical (603139.SH): Once again certified as a high-tech enterprise
Gelonghui, January 8, 丨 Kanghui Pharmaceutical (603139.SH) announced that it has recently received the “High-tech Enterprise Certificate” (certificate number: GR202361001397, date of issue: November 29, 2023, validity: three years) jointly issued by the Shaanxi Provincial Department of Science and Technology, the Shaanxi Provincial Department of Finance, and the Shaanxi Provincial Taxation Bureau of the State Administration of Taxation.
Kanghui Pharmaceutical (603139.SH): The company's compound Shuanghua tablets have the effect of clearing heat and detoxifying, relieving throat swelling
Gelonghui, January 4 | Kanghui Pharmaceutical (603139.SH) said on the investor interactive platform that the company's compound Shuanghua tablets have the effect of clearing heat and detoxifying, relieving swelling, and are mainly used for wind heat and wind heat milkworms. Symptoms include fever, slight wind, headache, nasal congestion, red and sore throat, or dry and burning throat; worsening when swallowing; red and swollen tonsils; red moss on the tip of the tongue or red lichen yellow on the tongue; fresh snow has anti-inflammatory and antipyretic effects, and is mainly used for fever caused by various febrile diseases, such as tonsillitis, upper respiratory tract inflammation, pharyngitis, tracheitis, high fever caused by colds, and fever. Compound double flower tablets
Kanghui Pharmaceutical (603139.SH): Director and Executive Deputy General Manager Yang Jin has increased her total holdings by 55,000 shares. The plan to increase her holdings has been implemented
Gelonghui, December 28, 丨 Kanghui Pharmaceutical (603139.SH) announced that as of December 28, 2023, Ms. Yang Jin, the director and executive deputy general manager, had increased her holdings of the company by 55,000 shares through centralized bidding transactions through the Shanghai Stock Exchange system, accounting for 0.0551% of the company's total share capital, with a cumulative increase of 1,040,600 yuan. The current plan to increase holdings has been implemented.
Kanghui Pharmaceutical (603139.SH) plans to invest in Qin Pharmaceutical Technology Research Company to mainly carry out research and development of common technologies of traditional Chinese medicine
Kanghui Pharmaceutical (603139.SH) issued an announcement to better solve key technical issues common to the traditional Chinese medicine industry and promote...
Kanghui Pharmaceutical (603139.SH) won an increase of 10,000 shares by Yang Jin, director and executive deputy general manager
Kanghui Pharmaceutical (603139.SH) issued an announcement. Yang Jin, director and executive deputy general manager of the company, in December 2023...
Kanghui Pharmaceutical (603139.SH): TBP reduced its shares by a total of 0.988%
Gelonghui on December 1丨Kanghui Pharmaceutical (603139.SH) announced that the company received TBP Traditional Medicine InvestmentHoldings (H.K.) The “Notice Letter on Expiration of the Stock Reduction Period and the Results of the Reduction of Shareholding” issued by Limited. As of the date the letter was issued, the period of the current holdings reduction plan had expired. Within the implementation range of this holdings reduction plan, TBPTraditional Medicine Investment Holdings (H.K.) Li
Kanghui Pharmaceutical (603139.SH): All new pharmaceutical production bases have been built
Gelonghui November 30: Some investors asked Kanghui Pharmaceutical (603139.SH) on the investor interactive platform, “Has the company submitted an application for the GMP inspection company to build a new pharmaceutical production base?” The company said that all of the company's new pharmaceutical production bases have been built, and preparations for GMP compliance checks are currently being carried out. If relevant progress is made in the future, the company will promptly issue relevant announcements.
Kanghui Pharma Sanctioned Over Failure to Disclose M&A Deal
Shaanxi Kanghui Pharmaceutical (SHA:603139) was sanctioned by the Shaanxi Securities Regulatory Bureau for failing to properly disclose material information related to its acquisition of Sichuan Chuns
Kanghui Pharmaceutical (603139.SH) and related personnel accepted the regulatory measures decision of the Shaanxi Securities Regulatory Bureau
Kanghui Pharmaceutical (603139.SH) issued an announcement. The company recently received the Shaanxi Supervision of the China Securities Regulatory Commission...
[BT Financial Report Instantaneous Analysis] Kanghui Pharmaceutical's 2023 Quarterly Report: Balance Ratio Rises, Net Profit Declines, Net Cash Flow Significantly Reduced
This financial report was announced on 2023-10-27 15:36:12 Kanghui Pharmaceutical (stock code: 603139) is a company that has been focusing on the medical and health industry for a long time. Its main business includes the pharmaceutical manufacturing industry and pharmaceutical distribution industry. In the pharmaceutical manufacturing industry, the company is mainly engaged in R&D, production and sales of proprietary Chinese medicines, covering the treatment of diseases such as dermatology, respiratory colds, gynecology, and orthopedics. In the pharmaceutical distribution industry, the company is mainly engaged in sales and distribution services for biological products, blood products and pharmaceuticals. In terms of assets and liabilities, Kanghui Pharmaceutical's total assets for the third quarter of 2023 are 21
Kanghui Pharmaceutical (603139.SH): Net profit of 9.22 million yuan in the first three quarters fell 43.3% year on year
On October 27, Kanghui Pharmaceutical (603139.SH) released its third quarter report. Operating income was 472 million yuan, up 25.88% year on year, net profit was 9.22 million yuan, down 43.3% year on year, net profit was 9.22 million yuan, down 43.3% year on year, non-net profit was 5.556 million yuan, down 50.78% year on year, and basic earnings per share were 0.09 yuan.
Kanghui Holdings, the controlling shareholder of Kanghui Pharmaceutical (603139.SH), did not reduce its holdings at the end of the reduction period
Kanghui Pharmaceutical (603139.SH) announced that the controlling shareholder of the company, Shaanxi Kanghui Holdings Co., Ltd. (“Kanghui Holdings”)...
Kanghui Pharmaceutical (603139.SH): Shaanxi Youbang currently does not have the production capacity for smeglutide and tepoleptide intermediates
Glonghui, Oct. 16丨Kanghui Pharmaceutical (603139.SH) announced a clarification notice. Shaanxi Youbang is currently carrying out small trial production of smeglutide and tepolotide intermediates. After the trial is completed, it is still necessary to complete the pilot phase before large-scale production can be carried out. Currently, Shaanxi Youbang does not have the production capacity for smeglutide and tepoleptide intermediates.
Analysis
Price Target
No Data
